PharmatecaPharmatecaФарматека2073-40342414-9128Bionika Media278631ArticlesСтатьиPOTENTIALS FOR USE OF DIPEPTIDYL PEPTIDASE-4 INHIBITORS IN TYPE 2 DIABETES MELLITUS: INITIATION AND CONTINUATION OF THERAPYПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ ИНГИБИТОРОВ ДИПЕПТИДИЛПЕПТИДАЗЫ-4 ПРИ САХАРНОМ ДИАБЕТЕ ТИПА 2: ИНИЦИАЦИЯ И ПРОДОЛЖЕНИЕ ТЕРАПИИAntsiferovM BZilovA VAntsiferovMikhail BorisovichАнциферовМихаил Борисович

Эндокринологический диспансер Департамента здравоохранения Москвы

ZilovAleksey VadimovichЗиловАлексей Вадимович

Первый МГМУ им. И.М.Сеченова, Москва

Эндокринологический диспансер Департамента здравоохранения МосквыПервый МГМУ им. И.М.Сеченова, Москва200820101716NO16 (2010)№16 (2010)121723022023Copyright ©; 2010, Bionika MediaCopyright ©; 2010, ООО «Бионика Медиа»2010Bionika MediaООО «Бионика Медиа»https://journals.eco-vector.com/2073-4034/article/view/278631

The article is dedicated to the modern potentials for use of dipeptidyl peptidase-4 (DPP-4) inhibitors, which recently were introduced in clinical practice. The main mechanism of action of these drugs is based on the increase of activity of incretin hormones by blocking the DPP-4 enzyme. Currently, the DPP-4 inhibitors are considered along with metformin as first-line agents for the treatment of type 2 diabetes mellitus (glycated hemoglobin level 6.5-7.5%) and as drugs for combination therapy in all phases of the continuation of therapy. To date, two drugs in this group are registered in the Russian Federation: Vildagliptin (Galvus, and its combination with metformin Galvus Met) and Sitagliptin (Januvia). Combined medication vildagliptin with metformin (Galvus Met) is available in different doses (50/500, 50/850 and 50/1000 mg), that helps to select the optimal daily dose and increase the patient's compliance. One of the advantages of these drugs is the possibility of their use in groups of elderly patients, patients with cardiovascular risk, arterial hypertension, and moderate renal dysfunction.

Рассматриваются современные возможности применения ингибиторов дипептидилпептидазы-4 (ДПП-4), которые недавно начали применяться в клинической практике. Механизм действия этих препаратов основан на повышении активности инкретиновых гормонов путем блокирования фермента ДПП-4. В настоящее время ингибиторы ДПП-4 рассматриваются наряду с метформином как препараты первой линии в лечении сахарного диабета типа 2 (при уровне гликированного гемоглобина 6,5-7,5 %) и далее на всех этапах продолжения терапии в качестве препаратов для комбинированной терапии. В настоящее время в РФ зарегистрировано два препарата этой группы: вилдаглиптин (Галвус и его комбинация с метформином Галвус Мет) и ситаглиптин (Янувия). Комбинированный препарат вилдаглиптина с метформином в виде единой лекарственной формы (Галвус Мет) доступен в разных дозировках (50/500, 50/850 и 50/1000 мг), что позволяет успешно подбирать оптимальную суточную дозу и усиливать комплаентность пациентов. Одним из достоинств указанных препаратов является возможность их применения в группах пожилых пациентов, пациентов с сердечно-сосудистым риском, артериальной гипертензией, нарушением почечной функции средней тяжести.

type 2 diabetes mellitusoral hypoglycemic agentsglucagon-like peptide-1dipeptidyl peptidase-4 inhibitorsvildagliptinmetforminсахарный диабет типа 2пероральные сахароснижающие препаратыглюкагоноподобный пептид-1ингибиторы дипептидилпептидазы-4вилдаглиптинметформинAACE/ACE Consensus Statement Glycemic Control Algorithm. Endocr Pract 2009;15(6):540-59.UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.Ferrannini E, Fonseca V, Zinman B. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab 2009;11:157-66.Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206.DCCT/EDIC Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. N Engl J Med 2003;348:2294-303.Johnson JA, Majundar SR, Simpson SH, et al. Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes Diabetes Care 2002;25:2244-48.Evans JM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49:930-36.Tzoulaki I, Molokhia M, Curcin V. Risk ofcardiovascular disease and all cuase mortality among patientswith type 2 diabetes prescribed oral antidiabetes drugs: retrospectivecohort study using UK general practice research database. BMJ 2009;339:4731.Dormandy JA, Charbonnel B, Eckland DJ. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzoneClinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89.Betteridge DJ, DeFronzo RA, Chilton RJ. PROactive: time for a critical appraisal. Eur Heart J 2008;29:969-83.Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-88.Mannucci E, Monami M, Lamanna C, et al. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008;10:1221-38.Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cuase mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.Rosenstock J, et al. Diabetes Care 2007;30:217-23.Evans JM, Ogston SA, Emslie-Smith A, et al. Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 2006;49:930-36.Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cuase mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218.He YL, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol 2007;47:633-41.Bosi E, Camisasca RP, Collober C, et al. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30:890-95.Ahren B, Gomis R, Standl E, et al. Twelveand 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004;27:2874-80.Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 2009;11:157-66.Marfella R, et al. Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations J Diabetes Complications 2010;24:79-83.Gore B, et al. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. Horm Metab Res 2008;40:892-95.